With the market becoming flooded with multiple biologics in inflammatory bowel disease, it will be crucial for Eli Lilly to strategically position its only therapy in this indication.
29 May 2019 Comment
22 May 2019 Comment
The pediatric pneumococcal vaccine market is exceptionally lucrative, with PCV13 achieving global sales of $5.8 billion in 2018; therefore Pfizer stands to lose substantial income if Merck's V114 can garner...
17 May 2019 Comment
GlobalData believes that Skyrizi’s strong results from the four Phase III trials demonstrate the drug can be a strong contender in the highly competitive psoriasis market.
14 May 2019 Analysis
The theme of this year’s Mental Health Awareness Week is the connection between body image and mental health. There is an established two-way link between mental health conditions and psoriasis;...
23 April 2019 News
Global pharmaceutical company Eli Lilly has announced top line results for Taltz (ixekizumab) in non-radiographic axial spondyloarthritis (nr-axSpA).
23 April 2019 projects
The University of Southampton’s Centre of Cancer Immunology is situated at Southampton General Hospital.
18 April 2019 Comment
The FDA has approved Dovato (dolutegravir/lamivudine) for the treatment of human immunodeficiency virus (HIV) in adults who have not previously received antiretroviral therapy (ART).
5 April 2019 News
Gilead has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for antiviral Descovy (emtricitabine and tenofovir alafenamide) for pre-exposure prophylaxis (PrEP) to reduce...
1 April 2019 News
AstraZeneca has announced the US Food and Drug Administration (FDA) has granted selumetinib, a MEK 1/2 inhibitor co-commercialised with Merck, breakthrough therapy designation.
29 March 2019 News
Gilead Sciences and Galapagos NV have announced their drug filgotinib met its primary endpoint in week 24 of two Phase III trials, FINCH 1 and FINDCH 3, of rheumatoid arthritis...